Shares of Eurofins Scientific S.E. (OTCPink: ERFSF) have been trending upward in the early trades today. Eurofins stock closed the last session up 7.02 percent at $101.40, ranging from $97.00 to $104.27. Over the past month, ERFSF stock fell over -5.67%, with approximately 3.79K shares traded daily.
ERFSF stock has gained more than 61.65% in the past 12 months reaching a high of $112.50, valuing the company at $18.05B. Following the news that ERFSF stock had developed new detection and identification products, the ERFSF stock rose.
What were those products?
Testing for Life is Eurofins’ mission. In addition to more than 50,000 employees across over 800 laboratories in over 50 countries, ERFSF’s firms offer more than 200,000 different analytical methods.
A wide range of COVID-19 diagnostic products are being developed by ERFSF stock, especially in response to the danger of emerging mutations. ERFSF yesterday announced the launch of two new products:
- GSD NovaPrime Plus SARS-CoV-2
- GSD NovaType Select L452R SARS-CoV-2 (RUO)
A PCR test such as GSD NovaPrime Plus SARS-CoV-2 can detect major mutations in a variant, such as in the UK variant, in just one reaction.
The new test of its kind, GSD NovaType Select L452R SARS-CoV-2 (RUO), on the other hand, enables detection of critical variants, such as those found in India, the United States, and California.
ERFSF going forward:
Eurofins (ERFSF) stock has continued to invest in R&D to develop reliable, high-quality testing solutions for the SARS-CoV-2 virus and its variants, which is evident in these two new products that will not only benefit consumers but also the company as well.